Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man.
L-prolyl-L-leucyl-glycine amide (P.L.G.) has melanocyte-stimulating-hormone-inhibitory hormone (M.I.F.) activity. When injected intravenously as a bolus of 200 mg, it greatly potentiated the effect of an oral levodopa dose upon motor performance objectively measured by a battery of tests. This amelioration in motility was accompanied by improvement in intellectual functioning.
D000284:Administration, Oral; D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007980:Levodopa / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D009075:MSH Release-Inhibiting Hormone / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009068:Movement / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy
D000978:Antiparkinson Agents; D007980:Levodopa; D009075:MSH Release-Inhibiting Hormone